At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses the results of the phase 3 PERSIST-1 trial of the selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3, pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews